What Is Laquinimod?

Laquinimod is a chemical substance with a molecular formula of C19H17ClN2O3.

Laquinimod

Right!
Laquinimod is a chemical substance with a molecular formula of C19H17ClN2O3.
Chinese name
Laquinimod
Foreign name
Laquinimod
Molecular formula
C19H17ClN2O3
Molecular weight
356.80
Studies have found that laquinimod can completely inhibit chronic experimental autoimmune encephalomyelitis (chEAE) in rats by eliminating leukocyte infiltration in the central nervous system. And from a direct comparison of the exposed doses, laquinimod's immunosuppressive effect is 20 times that of roquinimod.
At the same time, it can inhibit the inflammatory factors CD4 + cells and macrophages from entering the central nervous tissue (ie, the spinal cord), and change the balance of cytokines, up-regulating the cytokines Th2 / Th3, IL-4, IL-10, and -transforming growth factor. This finding indicates that laquinimod is an immunomodulator and does not have a broad-spectrum immunosuppressive effect.
In addition, laquinimod can reduce inflammation, demyelination and axonal injury in EAE (experimental autoimmune encephalomyelitis) animal models, which can both anti-inflammatory and protect nerves. Its effect is dose-dependent and inhibitory. Stronger than Roquinac.
The study found that laquinimod has the characteristics of high bioavailability, low total clearance, and small apparent distribution volume in experimental animals such as rats, mice, rabbits and dogs.
On March 15, 2012, Teva and its partner, Active Biotech, Sweden, announced that a Phase III Allegro study showed that oral laquinimod is very effective in the treatment of recurrent and progressive multiple sclerosis (RRMS), which can slow inflammation and reduce brain tissue in patients. damage.
Phase III studies have shown that laquinimod is very safe and well tolerated.
GiancarloComi, a neurologist at San Rafael University of Life and Health in Italy, said: "The positive results of the Phase III Allegro study prove that laquinimod is very effective in the treatment of multiple sclerosis and can manage the nervous tissue of patients with multiple sclerosis. Damage. " [1-2]
Laquinimod's new drug application will be submitted to the European Medicines Agency later this year.

IN OTHER LANGUAGES

Was this article helpful? Thanks for the feedback Thanks for the feedback

How can we help? How can we help?